Skip Navigation


JAC Advance Access originally published online on October 26, 2007
Journal of Antimicrobial Chemotherapy 2008 61(1):224-225; doi:10.1093/jac/dkm405
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/1/224    most recent
dkm405v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Burkhardt, O.
Right arrow Articles by Kielstein, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burkhardt, O.
Right arrow Articles by Kielstein, J. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis

Olaf Burkhardt1, Christian Joukhadar2, Friederike Traunmüller2, Johannes Hadem3, Tobias Welte1 and Jan T. Kielstein4,*

1 Department of Pulmonary Medicine, Medical School Hannover, Hannover, Germany 2 J&P Medical Research Ltd, Vienna, Austria 3 Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany 4 Department of Nephrology, Medical School Hannover, Hannover, Germany

* Corresponding author. Tel: +49-511-532-6319; Fax: +49-511-532-4005; E-mail: Kielstein@yahoo.com

Keywords: Gram-positive infections , endocarditis , renal replacement therapy

The first 10% of the full text of this article appears below.

Sir,Daptomycin is a new intravenous cyclic lipopeptide antibiotic, representing a new class of antibiotics with a spectrum of activity similar to vancomycin. It is licensed in the USA and Europe for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms including both susceptible and resistant strains of Staphylococcus aureus at a dose of 4 mg/kg once daily.1 Additionally it has been licensed in both the USA and Europe for the treatment of various infections due to susceptible organisms, including serious and life-threatening Gram-positive infections, vancomycin-resistant enterococcal infections and . . . [Full Text of this Article]


   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. T. Kielstein, J. Lorenzen, V. Kaever, H. Burhenne, M. Broll, C. Hafer, and O. Burkhardt
Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis--a single case
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2283 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
O. Burkhardt, C. Hafer, A. Langhoff, V. Kaever, V. Kumar, T. Welte, H. Haller, D. Fliser, and J. T. Kielstein
Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis
Nephrol. Dial. Transplant., January 1, 2009; 24(1): 267 - 271.
[Abstract] [Full Text] [PDF]